U.S.-China Heparin Scare Could Affect Indian Drug Makers
This article was originally published in PharmAsia News
The scare surrounding tainted Chinese heparin could have an impact on Indian drug makers. The discovery that the active ingredient in blood-clotting drugs was tainted by Chinese suppliers has increased quality concerns by U.S. firms that obtain ingredients from China and India. Indian firms may be tempted to dismiss the concern as a problem China must deal with, but India often is mentioned as part of a general problem with sources of ingredients. One U.S. drug consultant says many companies are looking to Indian sources to replace Chinese sources, likely adding to U.S. scrutiny. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.